-
1 Comment
Clearside Biomedical, Inc is currently in a long term uptrend where the price is trading 100.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.8.
Clearside Biomedical, Inc's total revenue sank by 99.4% to $11K since the same quarter in the previous year.
Its net income has dropped by 129.7% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 366.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Clearside Biomedical, Inc gets an overall score of 2/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US1850631045 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 66M |
---|---|
PE Ratio | None |
Target Price | 5.8333 |
Beta | 2.04 |
Dividend Yield | None |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CLSD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025